Shots:
- The US FDA has approved Vyvgart Hytrulo (efgartigimod alfa & hyaluronidase-qvfc) prefilled syringe to treat AChR+ adults with generalized myasthenia gravis (gMG) & adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
- Approval was based on studies showing bioequivalence to Vyvgart Hytrulo vial, with human factors validation confirming that pts with gMG or CIDP, or their caregivers, could safely & successfully administer the prefilled syringe formulation
- Vyvgart Hytrulo prefilled syringe, developed with Halozyme’s Enhanze technology, allows 20 to 30 sec subcutaneous self-injection by pts, caregivers, or healthcare professionals after proper training
Ref: argenx | Image: argenx
Related News:- argenx and Zai Lab Report the NMPA’s Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
